Relation between plasma concentration and clinical efficacy after sublingual single dose apomorphine in Parkinson's disease

1991 ◽  
Vol 41 (5) ◽  
pp. 493-494 ◽  
Author(s):  
F. Durif ◽  
E. Jeanneau ◽  
F. Serre-Debeauvais ◽  
D. Deffond ◽  
A. Eschalier ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Single Dose ◽  
Plasma Concentration ◽  
Clinical Efficacy

scholarly journals Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease

2019 ◽  
Vol 7 (2) ◽  
pp. e00470 ◽  
Author(s):  
Fernando L. Pagan ◽  
Michaeline L. Hebron ◽  
Barbara Wilmarth ◽  
Yasar Torres‐Yaghi ◽  
Abigail Lawler ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Single Dose ◽  
Pharmacokinetics And Pharmacodynamics

scholarly journals Elevated GM3 plasma concentration in idiopathic Parkinson’s disease: A lipidomic analysis

PLoS ONE ◽  
2017 ◽  
Vol 12 (2) ◽  
pp. e0172348 ◽  
Author(s):  
Robin B. Chan ◽  
Adler J. Perotte ◽  
Bowen Zhou ◽  
Christopher Liong ◽  
Evan J. Shorr ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Plasma Concentration ◽  
Idiopathic Parkinson’S Disease ◽  
Lipidomic Analysis ◽  
Idiopathic Parkinson's Disease

scholarly journals L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson’s Disease: A Randomised Study

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Fabrizio Stocchi ◽  
Laura Vacca ◽  
Paola Grassini ◽  
Stephen Pawsey ◽  
Holly Whale ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Plasma Concentration ◽  
Pharmacokinetic Profile ◽  
Pharmacokinetic Parameters ◽  
Maximum Plasma ◽  
Double Blind ◽  
Time Curve ◽  
Randomised Study ◽  
Effervescent Tablet

Objectives.To characterize the pharmacokinetic profile of levodopa (L-dopa) and carbidopa after repeated doses of the effervescent tablet of melevodopa/carbidopa (V1512; Sirio) compared with standard-release L-dopa/carbidopa in patients with fluctuating Parkinson’s disease. Few studies assessed the pharmacokinetics of carbidopa to date.Methods.This was a single-centre, randomized, double-blind, double-dummy, two-period crossover study. Patients received V1512 (melevodopa 100 mg/carbidopa 25 mg) or L-dopa 100 mg/carbidopa 25 mg, 7 doses over 24 hours (Cohort 1), 4 doses over 12 hours (Cohort 2), or 2 doses over 12 hours in combination with entacapone 200 mg (Cohort 3). Pharmacokinetic parameters included area under the plasma-concentration time curve (AUC), maximum plasma concentration (Cmax), and time toCmax(tmax).Results.Twenty-five patients received at least one dose of study medication. L-dopa absorption tended to be quicker and pharmacokinetic parameters less variable after V1512 versus L-dopa/carbidopa, both over time and between patients. Accumulation of L-dopa in plasma was less noticeable with V1512. Carbidopa exposure and interpatient variability was lower when V1512 or L-dopa/carbidopa was given in combination with entacapone. Both treatments were well tolerated.Conclusions.V1512 provides a more reliable L-dopa pharmacokinetic profile versus standard-release L-dopa/carbidopa, with less drug accumulation and less variability. This trial is registered with ClinicalTrials.govNCT00491998.

Clinical efficacy of istradefylline on lower urinary tract symptoms in Parkinson's disease

2016 ◽  
Vol 23 (10) ◽  
pp. 893-894 ◽  
Author(s):  
Takeya Kitta ◽  
Ichiro Yabe ◽  
Ikuko Takahashi ◽  
Masaaki Matsushima ◽  
Hidenao Sasaki ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Clinical Efficacy ◽  
Lower Urinary Tract ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

Single-Dose Studies of a Slow-Release Preparation of Levodopa and Benserazide (Madopar HBS) in Parkinson’s Disease

1987 ◽  
Vol 27 (1) ◽  
pp. 54-58 ◽  
Author(s):  
M.H. Marion ◽  
F. Stocchi ◽  
S.L. Malcolm ◽  
N.P. Quinn ◽  
P. Jenner ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Single Dose ◽  
Slow Release ◽  
Release Preparation ◽  
Slow Release Preparation

Rotigotine for the Treatment of Advanced Parkinson's Disease

2009 ◽  
Vol 4 (2) ◽  
pp. 24
Author(s):  
Santiago Perez Lloret ◽  
Olivier Rascol ◽  
◽  
Keyword(s):  
Parkinson’S Disease ◽  
Drug Delivery ◽  
Parkinson's Disease ◽  
Clinical Efficacy ◽  
Transdermal Patch ◽  
Motor Complications ◽  
Once Daily ◽  
Rotigotine Patch ◽  
Continuous Drug Delivery ◽  
Rotigotine Transdermal Patch

Background: Rotigotine, a non-ergot dopamine agonist, has been developed as a novel transdermal formulation. The rotigotine transdermal patch is approved by the regulatory authorities for use in all stages of Parkinson’s disease (PD) in Europe and for early-stage PD in the US. For patients with advanced-stage PD and motor fluctuations, approved doses range from 4mg/24 hours to 16mg/24 hours. The rotigotine patch offers a certain number of potential advantages, including faster onset as intestinal absorption is not needed, continuous drug delivery and ease of use via application of a once-daily adhesive patch. An interesting element of this profile is continuous drug delivery, which may avoid the pulsatile dopaminergic stimulation that has been postulated to be related to the development of motor complications.Objective: The aim of this article is to review the pharmacokinetics, pharmacodynamics and clinical efficacy and tolerability of the rotigotine transdermal patch.Methods: Source material was identified using a PubMed search for the term ‘rotigotine’ in articles published up to October 2009 and a review of published congress abstracts. The review focused primarily on publications related to the rotigotine indication for advanced PD.Results and conclusions: The rotigotine transdermal patch demonstrates clinical efficacy and a tolerability profile that appears to be well within the range of that observed with other non-ergot dopamine agonists, except for local skin reactions, which are common with the rotigotine patch. The once-daily patch formulation may encourage compliance; however, as is the case for other theoretical advantages of continuous drug delivery, such as reduced emergence of motor complications and improved tolerance of peripheral adverse events, this requires further detailed study.

Sign in / Sign up

Export Citation Format

Share Document